Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) concluded the trading at $2.74 on Thursday, Jan 21, with a rise of 5.79% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $2.59 and 5Y monthly beta was reading 2.17 with its price kept floating in the range of $2.5700 and $2.8300 on the day. Company’s P/E ratio for the trailing 12 months is 0. Considering stock’s 52-week price range provides that CATB hit a high price of $8.59 and saw its price falling to a low level of $1.25 during that period. Over a period of past 1-month, stock came adding 26.85% in its value.
With its current market valuation of $57.1 Million, Catabasis Pharmaceuticals, Inc. is set to declare its quarterly results on November 12, 2020. CATB Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of -$0.45 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$2.01 for 2021 with estimates of that growing to -$0.69 in next year. These estimates are suggesting current year growth of -0.14% for EPS and -0.66% growth next year.
In contrast, when we review CATB stock’s current outlook then short term indicators are assigning it an average of Hold, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 100% Sell for it.
According to ratings assigned by 2 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 2 of them are recommending Catabasis Pharmaceuticals, Inc. (CATB) as a Hold, while none are in view that stock is a Buy. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Hold and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the CATB stock which is currently positioned at 0. It further provides that stock’s current price level is 16.52% away from its 20-day simple moving average and is 40% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 63.13 while volatility remained at 9.85% over the past week which changes to 8.65% when measuring it over the past month. Beta is valued at 2.17, while measure of average true range or ATR is currently at 0.2. In predicting price targets of as low as $24 and as high as $24, analysts are in agreement on assigning the stock over the next 12 months average price target of $24. Stock’s current price level is 775.91% above from estimated low price target while it is 775.91% below the estimated high; and even if the CATB’s share succeeded to reach the median price of $24, then the outlook of +775.91% could come to the excitement of the investors.
In comparing Catabasis Pharmaceuticals, Inc. (CATB)’s stock with other industry players reveals that stock’s current price change of +5.79% and that of -60.58% over the past 12 months is in competing position with that of Bristol-Myers Squibb Company (BMY) which saw its stock price fell by -3.12% in the last trading and went through a decline of -4.82% in past 12-month trading. Industry’s another major player Amgen Inc (AMGN) has fell -0.13% down in previous session, but over the past year has faced a rise of 6.45%, while Gilead Sciences Inc (GILD) was also up 5.79% however its price remained floating in the red at -60.58% over the same period. Catabasis Pharmaceuticals, Inc. has a P/E ratio of 0 against that of Bristol-Myers Squibb Company’s 0 while Amgen Inc is showing 20.32 for the same. On the other hand, the S&P 500 Index was up 0.03% in the last trading session while the Dow Jones Industrial closed the session lower at -0.04%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Having a second look at Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) provides that stock’s average daily trading volume for 3 months was 5.39 Million, while it jumped to 867.41 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 20.08 Million.
Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 0.13% while it is 40.64% for the institutional holders. The figures also indicate that as of December 30, 2020, number of stock’s short shares was 1720000 which implies a short ratio of 0.16. This shows up a 8.57% of Short Interest in company’s outstanding shares on the day. In December the standing of shares short declined as it was 469.95 Million in the previous month. Addition of +28.04% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
Even if you’re not actively in crypto, you deserve to know what’s actually going on…
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .